Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemostasis in malignancy.

S Nand1, H Messmore

  • 1Department of Medicine, Loyola University Stritch School of Medicine, Maywood, IL 60153.

American Journal of Hematology
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway.

Leukemia·2016
Same author

Primary talectomy for severe fracture-dislocation of the talus with a 15-year followup: case report.

Foot & ankle international·2007
Same author

Lymphoproliferative disorders in chronic hepatitis C.

Journal of viral hepatitis·2004
Same author

Herpes zoster during treatment with arsenic trioxide.

Annals of hematology·2004
Same author

Superior sagittal sinus thrombosis in a child with Down syndrome.

Journal of paediatrics and child health·2003
Same author

Estrogens for heart disease: a report from the annual session of the American College of Cardiology.

The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia·2001
Same journal

EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion-Dependent Thalassemia.

American journal of hematology·2026
Same journal

Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count.

American journal of hematology·2026
Same journal

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026
Same journal

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

American journal of hematology·2026
Same journal

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

American journal of hematology·2026
Same journal

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.

American journal of hematology·2026
See all related articles

Metastatic cancer frequently causes hemostatic abnormalities, including abnormal coagulation and platelet activation, impacting 95% of patients. However, these lab findings don't predict clinical bleeding or clotting complications.

Area of Science:

  • Oncology
  • Hematology
  • Pathophysiology

Background:

  • Metastatic cancer is frequently associated with hemostatic abnormalities.
  • These abnormalities involve platelet function, coagulation cascade activation, fibrinolysis, and anticoagulant protein synthesis.

Purpose of the Study:

  • To review the hemostatic abnormalities in metastatic cancer.
  • To discuss their clinical implications and therapeutic strategies.

Main Methods:

  • Review of literature on hemostasis in cancer.
  • Analysis of mechanisms of tumor-induced coagulopathy.
  • Discussion of clinical manifestations and treatment approaches.

Main Results:

  • Up to 95% of patients with metastatic cancer exhibit hemostatic abnormalities.

Related Experiment Videos

  • Tumor cells and macrophages release procoagulant factors like Tissue Factor.
  • Abnormalities do not reliably predict thromboembolic or hemorrhagic complications, occurring in 9-15% of patients.

    • Conclusions:

    • Therapy for tumor-related coagulopathy should be based on clinical presentation.
    • Subclinical disseminated intravascular coagulation (DIC) requires no treatment.
    • Warfarin may decrease procoagulant production; Coumadin is often ineffective for cancer thrombosis; heparin use in APL is debated.